SCHEMBL2695429

SCHEMBL2695429

COC(=O)c1ccc(CN2CC3(CCN(C(=O)OC(C)(C)C)CC3)CC2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC8 Q9BY41 1/20 0.51
PKM P14618 1/20 0.46
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
TP53 P04637 1/20 0.43
NAMPT P43490 6/20 0.42
CYP11B2 P19099 1/20 0.42
HTT P42858 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22770534 0.88 ALDH1A1 (0.46) HDAC1HDAC6HDAC8TP53LMNA
SCHEMBL2696809 0.88 HDAC1 (0.47) HDAC1HDAC6HDAC8TP53NAMPT
SCHEMBL2340026 0.87 HDAC1 (0.48) HDAC1HDAC6HDAC8JAK2JAK1
SCHEMBL12447685 0.86 OPRD1 (0.51) HDAC1HDAC6HDAC8TP53CYP11B2
SCHEMBL2694180 0.85 HDAC1 (0.45) HDAC1HDAC6HDAC8TP53NAMPT
SCHEMBL21753298 0.84 GPR119 (0.54)
SCHEMBL289645 0.82 ITGB3 (0.55) HDAC1PKMJAK2JAK1ITGB3
SCHEMBL12184200 0.81 HDAC1 (0.52) HDAC1HDAC6HDAC8PKMJAK2
SCHEMBL5313737 0.80 HDAC1 (0.61) HDAC1HDAC6HDAC8PKMJAK2
SCHEMBL10111390 0.79 USP2 (0.41) HDAC1HDAC6HDAC8NAMPTCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518945-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-08-27 US disclosed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 HDAC1 1599/4885HDAC6 1919/4885HDAC8 3188/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 HDAC1 2322/4885HDAC6 2319/4885HDAC8 3446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.